Efficacy and Safety of Citrate Anticoagulation in CRRT for Patients With Liver Failure/DysfuncTION, the CAUTION Trial! A Retrospective Study on Etiology of Liver Failure and Their Complications

Launched by UNIVERSITY HOSPITAL, ANTWERP · Apr 2, 2025

Keywords

ClinConnect Summary

The CAUTION Trial is a study looking at how well a special kind of blood thinner called citrate works for patients with liver failure who also have acute kidney injury (AKI) and are critically ill. Researchers want to find out if the cause of liver failure affects the number of complications related to citrate and how effective it is in helping patients recover their kidney function, maintain the equipment used in treatment, and improve survival rates.

To be eligible for this trial, you must be at least 18 years old and diagnosed with severe kidney injury requiring a treatment called continuous renal replacement therapy (CRRT). You should also have liver failure or significant liver dysfunction, along with evidence of shock, which means your blood pressure is very low despite treatment. If you join the study, you will help researchers gather important information that could improve care for patients in similar situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Critically ill patients diagnosed with AKI requiring CRRT. Caution Protocol V1.0 24-07-2024
• • Documented liver failure or significant liver dysfunction (e.g., elevated liver enzymes, bilirubin levels, or clinical diagnosis of liver failure) and clincal diagnosis of shock (NE of 0.25 μg/kg/min and or association of second vasopressor).
• • Age ≥ 18 years.
• Exclusion Criteria:
• • NA